Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.60
-1.14 (-0.99%)
Streaming Delayed Price
Updated: 10:43 AM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
October 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
October 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
September 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
September 24, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
September 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END
Via
FinancialNewsMedia
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
September 18, 2024
From
Merck & Co., Inc.
Via
Business Wire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
September 17, 2024
From
Daiichi Sankyo
Via
Business Wire
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
September 16, 2024
Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax.
Via
MarketBeat
Exposures
COVID-19
Product Safety
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat Week in Review – 9/9 - 9/13
September 14, 2024
Markets were mostly positive this week as benign inflation numbers did nothing to dampen expectations that the Federal Reserve will cut interest rates
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Summit Therapeutics Surges on Trial Results: Time to Buy?
September 12, 2024
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.
Via
MarketBeat
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
September 11, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
September 11, 2024
From
Merck & Co., Inc.
Via
Business Wire
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
September 07, 2024
From
Daiichi Sankyo
Via
Business Wire
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
September 07, 2024
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
Via
MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
September 06, 2024
Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?
Via
MarketBeat
Exposures
Product Safety
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
September 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
September 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
September 03, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
August 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
August 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.